| 723918 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors |
2021-08-01 |
10.1136/jitc-2021-003005 |
DeNardo David G, Galkin Anna, Dupont Jakob, Zhou Lei, Bendell Johanna |
| 723917 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models |
2021-08-01 |
10.1136/jitc-2021-002644corr1 |
|
| 723916 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas |
2021-08-01 |
10.1136/jitc-2021-002863 |
Piha-Paul Sarina A, Geva Ravit, Tan Tira J, Lim Darren WT, Hierro Cinta, Doi Toshikiko, Rahma Osama, Lesokhin Alexander, Luke Jason John, Otero Javier, Nardi Lisa, Singh Angad, Xyrafas Alexandros, Chen Xinhui, Mataraza Jennifer, Bedard Philippe L |
| 723915 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer |
2021-08-01 |
10.1136/jitc-2021-002597 |
Emens Leisha A, Adams Sylvia, Cimino-Mathews Ashley, Disis Mary L, Gatti-Mays Margaret E, Ho Alice Y, Kalinsky Kevin, McArthur Heather L, Mittendorf Elizabeth A, Nanda Rita, Page David B, Rugo Hope S, Rubin Krista M, Soliman Hatem, Spears Patricia A, Tolaney Sara M, Litton Jennifer K |
| 723914 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Recombinant Mycobacterium smegmatis delivering a fusion protein of human macrophage migration inhibitory factor (MIF) and IL-7 exerts an anticancer effect by inducing an immune response against MIF in a tumor-bearing mouse model |
2021-08-01 |
10.1136/jitc-2021-003180 |
Jeong Hyein, Lee So-Young, Seo Hyejun, Kim Bum-Joon |
| 723913 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding |
2021-08-01 |
10.1136/jitc-2020-002151 |
Lanitis Evripidis, Kosti Paris, Ronet Catherine, Cribioli Elisabetta, Rota Giorgia, Spill Aodrenn, Reichenbach Patrick, Zoete Vincent, Dangaj Laniti Denarda, Coukos George, Irving Melita |
| 723912 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Deregulation of HLA-I in cancer and its central importance for immunotherapy |
2021-08-01 |
10.1136/jitc-2021-002899 |
Hazini Ahmet, Fisher Kerry, Seymour Len |
| 723911 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report |
2021-08-01 |
10.1136/jitc-2020-001870corr1 |
|
| 723910 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers |
2021-08-01 |
10.1136/jitc-2021-002473 |
Naidoo Jarushka, Schreck Karisa C, Fu Wei, Hu Chen, Carvajal-Gonzalez Alexander, Connolly Roisin M, Santa-Maria Cesar A, Lipson Evan J, Holdhoff Matthias, Forde Patrick M, Douville Christopher, Riemer Joanne, Barnes Amanda, Redmond Kristin J, Kleinberg Lawrence, Page Brandi, Aygun Nafi, Kinzler Kenneth W, Papadopoulos Nickolas, Bettegowda Chetan, Venkatesan Arun, Brahmer Julie R, Grossman Stuart A |
| 723909 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Correction: BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis |
2021-08-01 |
10.1136/jitc-2019-000275corr1 |
|
